Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Foto på Mattias Ohlsson

Mattias Ohlsson

Professor

Foto på Mattias Ohlsson

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Författare

  • Sebastian Palmqvist
  • H. Zetterberg
  • N. Mattsson
  • Per Johansson
  • Lennart Minthon
  • K. Blennow
  • Mattias Ohlsson
  • Oskar Hansson
  • Jimmy Lätt

Summary, in English

Objective:To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD).Methods:From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). -Amyloid (A) deposition in 9 brain regions was examined with [F-18]-flutemetamol PET. CSF was analyzed with INNOTEST and EUROIMMUN ELISAs. The results were replicated in 146 controls and 64 patients with MCI-AD from the Alzheimer's Disease Neuroimaging Initiative study.Results:The best CSF measures for identifying MCI-AD were A42/total tau (t-tau) and A42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). The best PET measures performed similarly (AUC 0.92-0.93; anterior cingulate, posterior cingulate/precuneus, and global neocortical uptake). CSF A42/t-tau and A42/p-tau performed better than CSF A42 and A42/40 (AUC difference 0.03-0.12, p < 0.05). Using nonoptimized cutoffs, CSF A42/t-tau had the highest accuracy of all CSF/PET biomarkers (sensitivity 97%, specificity 83%). The combination of CSF and PET was not better than using either biomarker separately.Conclusions:Amyloid PET and CSF biomarkers can identify early AD with high accuracy. There were no differences between the best CSF and PET measures and no improvement when combining them. Regional PET measures were not better than assessing the global A deposition. The results were replicated in an independent cohort using another CSF assay and PET tracer. The choice between CSF and amyloid PET biomarkers for identifying early AD can be based on availability, costs, and doctor/patient preferences since both have equally high diagnostic accuracy.Classification of evidence:This study provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.

Avdelning/ar

  • Klinisk minnesforskning
  • Beräkningsbiologi och biologisk fysik - Har omorganiserats
  • Artificiell intelligens och thoraxkirurgisk vetenskap (AICTS)
  • Medicinsk strålningsfysik, Lund
  • MR Physics
  • MultiPark: Multidisciplinary research focused on Parkinson´s disease

Publiceringsår

2015

Språk

Engelska

Sidor

1240-1249

Publikation/Tidskrift/Serie

Neurology

Volym

85

Issue

14

Dokumenttyp

Artikel i tidskrift

Förlag

Lippincott Williams & Wilkins

Ämne

  • Neurosciences

Nyckelord

  • MILD COGNITIVE IMPAIRMENT
  • POSITRON-EMISSION-TOMOGRAPHY
  • CEREBROSPINAL-FLUID
  • ASSOCIATION WORKGROUPS
  • DIAGNOSTIC GUIDELINES
  • NATIONAL INSTITUTE
  • BETA
  • TAU
  • DEMENTIA
  • RECOMMENDATIONS

Aktiv

Published

Forskningsgrupp

  • Clinical Memory Research
  • Artificial Intelligence in CardioThoracic Sciences (AICTS)
  • MR Physics

ISBN/ISSN/Övrigt

  • ISSN: 1526-632X